title: Protective effect of infliximab on ischemia/reperfusion-induced damage in rat kidney.
abstract: OBJECTIVE
  To investigate the protective effect of infliximab on ischemia-reperfusion (I/R) injury of the rat kidney.
  
  
  METHODS
  Twenty-eight male Wistar albino rats were divided into four groups: sham-operated, I/R, I/R with infliximab administered before ischemia [I/R + infliximab (bi)], and I/R with infliximab administered before reperfusion [I/R + infliximab (br)]. After a right nephrectomy to produce damage, the left renal vessels were occluded for 60 min, followed by 24-h reperfusion in rats. Changes in the rat kidney were observed by measuring the tissue levels of malondialdehyde (MDA), myeloperoxidase (MPO), glutathione (GSH), and superoxide dismutase (SOD) and by evaluating hematoxylin-eosin (H&E)-stained and periodic acid-Schiff (PAS) sections.
  
  
  RESULTS
  The MDA and MPO levels in the I/R group were significantly higher than in the other groups (p < 0.05), and the SOD and GSH levels in the I/R + infliximab (bi) and I/R + infliximab (br) groups were significantly higher than in the I/R group (p < 0.05). However, histological examination revealed that the I/R + infliximab (bi) group and the I/R + infliximab (br) group had significantly fewer tubular changes and interstitial inflammatory cell infiltration than the I/R group.
  
  
  CONCLUSIONS
  These results show that infliximab may protect against I/R injury in the rat I/R model.
authors.affiliation: Department of Urology, Inonu University, Medical Faculty, Malatya, Turkey. tasdemrcemal@yahoo.com
authors.forename: Cemal
authors.initials: C
authors.lastname: Tasdemir
authors.forename: Seda
authors.initials: S
authors.lastname: Tasdemir
authors.forename: Nigar
authors.initials: N
authors.lastname: Vardi
authors.forename: Burhan
authors.initials: B
authors.lastname: Ates
authors.forename: Hakan
authors.initials: H
authors.lastname: Parlakpinar
authors.forename: Bulent
authors.initials: B
authors.lastname: Kati
authors.forename: Merve Goksin
authors.initials: MG
authors.lastname: Karaaslan
authors.forename: Ahmet
authors.initials: A
authors.lastname: Acet
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004195:Disease Models, Animal; D000069285:Infliximab; D007668:Kidney / Q000098:blood supply; D007684:Kidney Tubules / Q000187:drug effects / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism*; D009195:Peroxidase / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D000069285:Infliximab; D009195:Peroxidase